The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.

Question

Six frontier AI models put this at 22% by 26 Sept 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

22% — the median of 6 frontier models, resolving by 2031-09-26.

Answer

Gemini (Google): 27% — Turns on whether late-stage pipelines cluster enough to overcome FDA capacity constraints and strict safety review timelines. Peak annual FDA approvals for novel gene therapies hover between 3 and 7, requiring an unprecedented surge to hit 10. CBER faces persistent review-staffing bottlenecks, and commercial reimbursement hurdles have caused several sponsors to delay BLA filings. A major shift to platform-based manufacturing or relaxed surrogate endpoints by 2027 would rapidly accelerate approval volume.

Answer

Claude (Anthropic): 8% — FDA gene therapy approvals must roughly triple annual pace within four remaining years, unlikely but not impossible. Historical pace has been 2-5 novel gene therapy approvals per year even in record years like 2023-2024. Pipeline growth and CRISPR/AAV platforms are accelerating submissions, but review timelines and manufacturing scale-up remain bottlenecks. A surge in accelerated approvals or platform-based reviews for rare diseases could push a single year to 10, but no strong signal of this yet by 2026.

Answer

GPT (OpenAI): 37% — The outcome hinges on whether late-stage pipelines convert simultaneously without CMC, durability, or safety delays. FDA has approved only a handful of novel gene therapies annually; no prior year has approached ten. Sponsors must complete pivotal data, manufacturing validation, and BLA review in the same calendar year before 2030. A wave of positive registrational readouts plus multiple Priority Reviews in 2028-29 would raise this sharply.

Answer

Grok (xAI): 22% — Whether CBER throughput and late-stage pipeline yield a 10-approval year in 2027-29. Recent peak is 4-6 novel gene therapies/year (2023-25); 10 requires a doubling that review slots and CMC inspections have not shown. ~50-70 Phase 3 assets exist, yet high attrition, sequential BLAs, and manufacturing bottlenecks historically keep annual output well below 10. A clustered CRISPR/AAV wave for prevalent diseases in 2028-29 would raise odds; absent that, the rate stays in the mid-single digits.

Answer

DeepSeek (DeepSeek): 22% — This turns on whether the FDA's 2023-2026 gene-therapy approval pace roughly doubles within four years. The FDA cleared roughly 3-5 novel gene therapies per year in 2023-2025, so ten in one year requires a 2-3x acceleration. Manufacturing capacity, not clinical data, is the binding constraint; CBER review slots and vector supply must scale first. The 2023 Elevidys and Casgevy approvals show the pipeline exists, but most candidates are still in Phase 2 with 2028-2030 PDUFA dates.

Answer

Qwen (Alibaba): 7% — Approval pipeline would need to roughly triple its current pace within 3 calendar years, with no precedent for that acceleration. FDA approved ~3-4 novel gene therapies per year through 2025; even optimistic pipelines (ARM, ASGCT projections) show ~5-6 by 2028-29. Each approval requires a BLA with full CMC, clinical, and safety review; FDA review capacity and advisory committee scheduling are binding constraints. Would need a wave of AAV/AAV-adjacent products clearing Phase III simultaneously—no such clustering exists in current late-stage pipeline data.

The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.

A gene therapy targeting herpes simplex virus enters Phase 3 clinical trials before 2029.

A clinical trial begins treating human embryos with heritable germline gene editing before 2035.

An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.

LambdaVision begins clinical trials for its microgravity-assembled retinal implant by December 31, 2028.